Demographic and clinical characteristics of patients who received short-term versus prolonged LVAD support
| Characteristic | Group; mean ± SD or % | p value | ||
|---|---|---|---|---|
| All patients (n = 103) | < 1 year support (n = 66) | ≥ 1 year support (n = 37) | ||
| Age, yr | 50 ± 13 | 49 ± 13 | 52 ± 13 | 0.27 |
| Male sex | 71 | 79 | 59 | 0.68 |
| NYHA 3/4 | 84 | 81 | 92 | 0.14 |
| Ischemic | 37 | 34 | 43 | 0.35 |
| HeartMate II | 70 | 68 | 73 | 0.58 |
| Weight, kg | 79 ± 20 | 81 ± 19 | 73 ± 18 | 0.29 |
| Height, m | 1.7 ± 0.11 | 1.7 ± 0.11 | 1.7 ± 0.11 | 0.21 |
| BMI | 26.2 ± 5.3 | 26.6 ± 5.1 | 25.0 ± 4.8 | 0.46 |
| BSA, m2 | 1.9 ± 0.3 | 2.0 ± 0.3 | 1.8 ± 0.3 | 0.15 |
| Diabetes | 27 | 29 | 24 | 0.61 |
| Hypertension | 41 | 42 | 40 | 0.50 |
| PVD | 3 | 0.0 | 8.1 | 0.02 |
| Prev. sternotomy | 14 | 9.7 | 21 | 0.10 |
| CVA | 4.1 | 4.8 | 2.7 | 0.60 |
| ICD | 79 | 77 | 84 | 0.45 |
| CRT | 43 | 42 | 46 | 0.70 |
| CRF | 33 | 37 | 24 | 0.19 |
| Creatinine Pre | 1.4 ± 0.6 | 1.5 ± 0.6 | 1.3 ± 0.5 | 0.22 |
| Bilirubin Pre | 1.4 ± 0.9 | 1.6 ± 1.0 | 1.1 ± 0.6 | 0.20 |
| AST Pre | 31.1 ± 23.0 | 33.5 ± 27.0 | 27.3 ± 15.7 | 0.24 |
| ALT Pre | 33.1 ± 33.6 | 35.4 ± 41.0 | 29.5 ± 19.0 | 0.44 |
| Albumin Pre | 3.54 ± 0.46 | 3.46 ± 0.48 | 3.64 ± 0.40 | 0.05 |
| LVEF | 18.8 ± 5.0 | 18.8 ± 5.9 | 18.7 ± 3.6 | 0.96 |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; BSA = body surface area; CRF = chronic renal failure; CRT = cardiac resynchronization therapy; CVA = cerebral vascular accident; ICD = implantable cardioverter defibrillator; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PVD = peripheral vascular disease; SD = standard deviation.